These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 28525374)

  • 1. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
    Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
    PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
    Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
    Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
    Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.